Harvey Adams

Harvey Adams

Harvey specialises in contentious inter partes proceedings before the European Patent Office and has considerable experience in both oppositions and appeals. Harvey won the Strode and Ballantyne prizes from the UK Chartered Institute of Patent Attorneys when qualifying as a UK Patent Attorney.

Harvey Adams


Year joined: 1999

Qualifications: MBiochem (Oxon) CPA EPA


Harvey’s particular area of expertise is in the conduct of contentious inter partes proceedings before the European Patent Office, although he applies this first-hand knowledge to his high value prosecution practice so as to maximise the strength of his clients’ patents against subsequent opposition or litigation. He is proficient at handling contentious cases involving parallel proceedings in multiple jurisdictions and has considerable experience in the conduct of pan-European litigation. He also has expertise in the procurement of and challenge to SPCs, in regulatory data protection and marketing exclusivity, and in the patent and regulatory law surrounding orphan drugs.

Harvey works in the fields of biotechnology, biochemistry, molecular biology and organic chemistry, with particular expertise in antibodies and immunology, pharmaceuticals, gene therapy, and diagnostics. 


Harvey has a Master’s degree in biochemistry with pharmacology (First class) from the University of Oxford, where he was awarded the University’s Gibbs prize. He also holds a Certificate in Intellectual Property from the University of London (Distinction) and a Diploma in Intellectual Property Litigation from Nottingham Law School (Distinction).

Membership & Organisations

Chartered Patent Attorney; European Patent Attorney; European Design Attorney; and European Trade Mark Attorney.

Recent Work

Over the last 20 years, Harvey has been involved in numerous key disputes within the fields of biotechnology and pharmaceuticals, including inter alia Ladner / McCafferty (phage display), Noelle / Lederman (antibodies to CD40CR), and the oppositions against the Queen estate (antibody humanisation). He has been entrusted with the defence of commercially valuable patents protecting important drugs such as Avonex® (interferon beta), Temodal® (temozolomide), Clarinex® (desloratadine), Myozyme® (alpha glucosidase), Lexiva® / Telzir® (fosamprenavir), Soliris® (eculizumab), Eloctate® (recombinant factor VIII), Alprolix® (recombinant factor IX), Velcade® (bortezomib), Norvir® (ritonavir), Kaletra® (ritonavir and lopinavir), Ninlaro® (ixazomib citrate), and Humira® (adalimumab). He has successfully opposed European patents too numerous to mention, specialising in the areas of antibodies, peptides, small molecule pharmaceuticals, and diagnostic technologies.  

Follow us on twitter